C

Prof. Thomas Krieg, FESC

托馬斯·克裏格 教授

University of Cambridge
PT

職位

Clinical Professor for Experimental Cardiovascular Medicine, University of Cambridge

劍橋大學臨床實驗心血管醫學教授

所屬機構

Honorary Consultant Physician, Cambridge University Hospitals NHS Foundation Trust · Fellow of the European Society of Cardiology, FESC

研究興趣

缺血/再灌注損傷線粒體代謝與氧化還原調節
個人簡介
Prof. Thomas Krieg是劍橋大學臨床試驗心血管醫學教授、歐洲心臟病學會院士，他是一位兼具學術造詣與臨床實踐經驗的學者。他於德國弗萊堡大學獲得醫學博士學位，持有英國醫學總會全科醫學與臨床藥理學專科註冊資質，現任劍橋大學阿登布魯克醫院榮譽顧問醫師。 他的研究聚焦於心肌缺血/再灌注損傷機制，他突破性發現了琥珀酸積累是心梗、中風後組織損傷的關鍵標誌物，其相關成果發表於《Nature》。作為KRIEG LAB負責人，他牽頭多項英國心臟基金會資助項目，深耕線粒體代謝與氧化還原調節研究，推動心肌保護藥物向臨床轉化。同時，他通過學術合作、科普傳播及人才培養，為全球心血管醫學領域貢獻力量，是基礎研究與臨床應用結合的典範學者。
出版物

  • Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS

    Chouchani, E. T., Pell, V. R., Gaude, E., ... & Krieg, T. (2014). Nature, 515(7527), 431-435.

    https://doi.org/10.1038/nature13909

  • Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I

    Chouchani, E. T., Methner, C., ... & Krieg, T. (2013). Nature Medicine, 19(6), 753-759.

    https://doi.org/10.1038/nm.3212

  • A unifying mechanism for mitochondrial superoxide production during ischemia-reperfusion injury

    Chouchani, E. T., Pell, V. R., James, A. M., ... & Krieg, T. (2016). Cell Metabolism, 23(2), 254-263.

    https://doi.org/10.1016/j.cmet.2015.12.009

  • Succinate metabolism: a new therapeutic target for myocardial reperfusion injury

    Pell, V. R., Chouchani, E. T., Frezza, C., Murphy, M. P., & Krieg, T. (2016). Cardiovascular Research, 111(2), 134-141.

    https://doi.org/10.1093/cvr/cvw100

  • Moving forwards by blocking back-flow: the yin and yang of MI therapy

    Pell, V. R., Chouchani, E. T., Murphy, M. P., Brookes, P. S., & Krieg, T. (2016). Circulation Research, 118(6), 898-906.

    https://doi.org/10.1161/CIRCRESAHA.115.306569

  • Metabolomic profiling in acute ST-segment-elevation myocardial infarction identifies succinate as an early marker of human ischemia-reperfusion injury

    Kohlhauer, M., Dawkins, S., ... & Krieg, T. (2018). Journal of the American Heart Association, 7(8), e007546.

    https://doi.org/10.1161/JAHA.117.007546

  • Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: Insights from MRI/PET imaging

    Methner, C., Buonincontri, G., ... & Krieg, T. (2014). PLoS One, 9(12), e115219.

    https://doi.org/10.1371/journal.pone.0115219

  • BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts

    Krieg, T., Liu, Y., ... & Downey, J. M. (2009). European Heart Journal, 30(13), 1607-1613.

    https://doi.org/10.1093/eurheartj/ehp143
參考課題
  • Introduction to Cardiovascular Diseases and Ischemia/Reperfusion Injury · 心血管疾病與缺血/再灌注損傷概論
  • Delving into the Pathological Mechanisms · 病理機制探究
  • Exploring Therapeutic Opportunities and Interventions · 探索治療機會和干預措施
  • Future Directions in Drug Development · 藥物發展的未來方向
  • Navigating the Complexities of Drug Development · 駕馭藥物開發的複雜性
  • Charting a Course for Future Research and Career Development · 為未來的研究和職業發展規劃課程